IL-23 Licenses Pathogenic Th17 Transdifferentiation via STAT4-dependent Upregulation of IL-12Rβ2
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Th17 cells exhibit substantial developmental plasticity, transdifferentiating into pathogenic, interferon-γ (IFN-γ)–producing Th1-like effectors during chronic autoimmune inflammation. While both IL-23 and IL-12 are implicated in this process, how these structurally related cytokines coordinate to drive transdifferentiation remains unresolved. Here, we show that IL-23 acts as a developmental licensor rather than a terminal trigger, priming Th17 cells for transdifferentiation upon subsequent IL-12 encounter. IL-23 signals through STAT4 to upregulate the IL-12–specific receptor subunit IL-12Rβ2, lowering the signalling threshold for IL-12. This licensing can be conferred at both early and late stages of Th17 development and produces a temporal logic in which IL-23-mediated STAT4 signaling functionally arms Th17 cells to terminally transdifferentiate in response to IL-12. Using Stat4 conditional knockouts and a structure-based IL-23 mutein that selectively abolishes IL-23–driven STAT4 signaling while preserving STAT3-dependent lineage maintenance, we genetically establish the IL-23–STAT4–IL-12Rβ2 axis as a discrete licensing module. Furthermore, using the adoptive Th17 transfer colitis model, we show that host-derived IL-23 and IL-12 are required for Th17-driven colitis, and the inflamed colonic environment reconstitutes transdifferentiation capacity in classically “non-pathogenic” Th17 cells. These findings reframe the pathogenic dichotomy of Th17 cells as one of cumulative cytokine exposure rather than fixed cellular fate, and reveal a stepwise architecture of Th17 plasticity in which IL-23 licensing and IL-12 triggering operate as functionally distinct events.
Significance Statement
Th17 cells protect mucosal barriers but can convert into pathogenic, IFN-γ-producing effectors that drive inflammatory bowel disease (IBD). Although IL-23 is essential for this conversion, the underlying molecular mechanism remains elusive. We show that IL-23 does not directly trigger transdifferentiation but instead licenses Th17 cells for this conversion, during both early and late stages of their development. By signaling through STAT4, IL-23 upregulates the IL-12–specific receptor subunit IL-12Rβ2 on Th17 cells, rendering them responsive to subsequent IL-12 exposure. Our findings reframe the classical “pathogenic” versus “non-pathogenic” Th17 distinction and provide a mechanistic basis for the clinical efficacy of IL-23–targeted therapies in IBD.
